ArticlePloS one2026
Imaging strategies for follow-up during adjuvant nivolumab in esophageal cancer: A multicenter retrospective cohort study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAdjuvant nivolumab improves disease-free survival in patients with esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy and resection, but recurrence risk remains high. Optimal follow-up strategies for early detection of recurrence during nivolumab treatment are lacking.
methodsIn this multi-center, retrospective cohort study, patients from three hospitals in the Netherlands who underwent surgical resection between September 2021 and October 2023 and received adjuvant nivolumab were included. Data on tumor type, treatment, and imaging intervals (every 3 months vs every 4 months) were collected. Primary outcome was disease recurrence, secondary outcomes included disease-free survival (DFS), and diagnostic yield of CT scans.
resultsOf 353 patients that underwent resection, 151 received at least one dose of adjuvant nivolumab (82% male; median age 66 years; 86% adenocarcinoma). A total of 27 patients (18%) developed on-treatment recurrent disease, which was detected by routinely performed CT scans in 67% and included distant metastasis in 89%. DFS was 89% at 4 months, 84% at 8 months, and 75% at 12 months, showing a gradual decline over time. The diagnostic yield of CT scans increased from 0% at baseline to 9% at 4 months.
conclusionRoutine baseline CT imaging did not detect recurrences, while routine imaging during adjuvant nivolumab identified the majority of recurrences. The gradual decline in disease-free survival suggests that recurrences are distributed over time, supporting a routine imaging interval, such as every 3 or 4 months as used in our study. These real-world data may help inform clinicians, and future studies can further evaluate optimal imaging intervals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.